In this video interview from the 2026 AACR Annual Meeting, Irene Ghobrial, MD, professor of medicine at Dana-Farber Cancer Institute, and Omar Nadeem, MD, clinical director of the Myeloma Immune Effector Cell Therapy Program at Dana-Farber Cancer Institute and assistant professor of medicine at Harvard Medical School, sit down with SOHO Insider to discuss results from the phase II CAR-PRISM trial and the impact of ciltacabtagene autoleucel (cita-cel; Carvykti) on high-risk smoldering multiple myeloma.
The discussion also covers the study’s safety profile and the potential for these early-stage immunotherapies to achieve long-term curative results.
Reference
Nadeem O, Cordas dos Santos F, Ghobrial I. BCMA-directed CAR T-cell therapy may be effective against high-risk smoldering multiple myeloma. Abstract# CT103. Presented at the American Association for Cancer Research (AACR) Annual Meeting 2026; April 17–22, 2026; San Diego, California.
Leave feedback about this